Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Myeloid 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Ovarian Neoplasms 32Testicular Neoplasms 13Carcinoma, Ovarian Epithelial 9Testicular Germ Cell Tumor 7Teratoma 7Ovarian Germ Cell Cancer 7Sarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Central Nervous System Neoplasms 4Osteosarcoma 3Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Endodermal Sinus Tumor 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Uterine Cervical Neoplasms 2Seminoma 2Recurrence 2Optic Nerve Glioma 2Neuroblastoma 2Melanoma 2Medulloblastoma 2Gestational Trophoblastic Disease 2Drug-Related Side Effects and Adverse Reactions 2Desmoplastic Small Round Cell Tumor 2Chondrosarcoma 2Carcinoma, Embryonal 2Brenner Tumor 2Breast Neoplasms 2

Interventions

Paclitaxel 7Cisplatin 6pembrolizumab 5Carboplatin 5Bevacizumab 5liposomal doxorubicin 3Gemcitabine 3trebananib 2niraparib 2interferon gamma-1b 2dostarlimab 2catumaxomab 2atezolizumab 2anlotinib 2Topotecan 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Itraconazole 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2vosaroxin 1vistusertib 1pertuzumab 1peginterferon alfa-2b 1olaparib 1nintedanib 1lanreotide 1epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Etoposide × Gynecologic × Clear all
NCT05910177 2024-03-06

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Fujian Cancer Hospital

Phase 2 Recruiting
30 enrolled
Gynecologic

Carcinoma, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡